Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Steroid-Refractory Chronic GVHD
NCT00136396Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2004
- Primary completion
- Nov 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in chronic graft-versus-host disease (cGVHD), sponsored by Dana-Farber Cancer Institute. Started Jan 2004; status: completed.
02
Drugs
rituximab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT00136396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00136396.